Approval · Notice of Compliance 17548 · 2015
NUCALA: Notice of Compliance 17548
Issued December 3, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17548
- Date
- December 3, 2015
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NUCALA | 02449781 | Cancelled Post Market |
Medicinal ingredients
- MEPOLIZUMAB 144 MG per VIAL